ISSN:
1573-8280
Keywords:
interleukin-2 (IL2)
;
lymphatic administration
;
lymphocyte cytotoxicity
;
lymphoma
;
melanoma
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract During this phase I/II study, enodolymphatic cannulae were placed in the iliac lymphatics under general anaesthesia. IL2 was then infused via this route at escalating doses until the highest tolerated dose was achieved; then, continuous infusion was maintained for 2 to 3 weeks. Seven patients with advanced cancer (3 lymphoma, 4 melanoma), resistant to all other modalities of treatment received such therapy. Most patients tolerated 4 to 5 × 106 u/day of IL2 for 2 to 3 weeks with less toxicity as compared to the equivalent dosage given intravenously. No severe perioperative morbidity was experienced. One melanoma patient had a minor clinical response. Changes in circulating lymphocyte numbers and cytotoxicity demonstrated a systemic effect of endolymphatic IL2 therapy. Conclusions: The endolymphatic administration of IL2 is associated with less toxicity than the intravenous route but still achieves a systemic effect; a lower tumour burden may prove more responsive to this therapy.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF02172654
Permalink
